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License 4.0 (CC BY-NC).Structural basis of sterol recognition by human
hedgehog receptor PTCH1
Chao Qi1, Giulio Di Minin2, Irene Vercellino3*, Anton Wutz2, Volodymyr M. Korkhov1,3†
Hedgehog signaling is central in embryonic development and tissue regeneration. Disruption of the pathway is
linked to genetic diseases and cancer. Binding of the secreted ligand, Sonic hedgehog (ShhN) to its receptor
Patched (PTCH1) activates the signaling pathway. Here, we describe a 3.4-Å cryo-EM structure of the human
PTCH1 bound to ShhNC24II, a modified hedgehog ligand mimicking its palmitoylated form. The membrane-embedded
part of PTCH1 is surrounded by 10 sterol molecules at the inner and outer lipid bilayer portion of the protein. The
annular sterols interact at multiple sites with both the sterol-sensing domain (SSD) and the SSD-like domain (SSDL),
which are located on opposite sides of PTCH1. The structure reveals a possible route for sterol translocation across
the lipid bilayer by PTCH1 and homologous transporters. o
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 INTRODUCTION
The hedgehog pathway is one of the key mechanisms of the devel-
opmental patterning in mammalian embryonic development and is
essential in tissue regeneration and homeostasis (1, 2). Disrupting
mutations in the components of the hedgehog pathway are linked
to diseases such as holoprosencephaly (3), Curry-Jones syndrome
(4), and Gorlin syndrome (5). Furthermore, abnormal hedgehog
pathway activation is associated with different forms of cancer, includ-
ing medulloblastoma and basal cell carcinoma (6, 7).
The hedgehog morphogens are small secreted proteins. Three
homologous hedgehog ligands have been identified in mammals: Sonic
(Shh), Desert (Dhh), and Indian (Ihh) hedgehog (8). Shh is the best
studied of the three and is presumed to play the key role in the hedgehog
pathway (9). The processed form of Shh is posttranslationally palmi-
toylated at its N-terminal residue C24 (10). Furthermore, the protein
undergoes autoproteolysis, leading to production of the mature
ShhN fragment that contains a C-terminal cholesteryl moiety (11). The
dually lipid-modified ShhN is released from the hedgehog-producing
cells and can elicit short- and long-range hedgehog pathway activation
in the developing embryo (12). The hedgehog pathway is activated in
the hedgehog-receiving cells upon binding of the hedgehog ligand to its
receptor, protein patched homolog 1 (PTCH1), along with several re-
cently identified coreceptors (13, 14). In the absence of ShhN, PTCH1
suppresses the activity of smoothened homolog (SMO), a G protein–
coupled receptor (15). Upon binding of ShhN to PTCH1, SMO trans-
locates to the Ellis-van Creveld (EvC) zone of the primary cilium (16)
and activates the GLI family of transcription factors, the hallmark of
the hedgehog signaling pathway activation (17).
PTCH1 is a member of the resistance-nodulation-division (RND)
transporter family (18). It is a 12–transmembrane (TM) domain mem-
brane protein, featuring two extended ectodomains that are involved in
ligand recognition. The TM2–6 bundle of PTCH1 is annotated as the
sterol-sensing domain (SSD) based on sequence similarity with similar
domains in proteins involved in cholesterol homeostasis (18, 19). The
SSD is presumed to be involved in the interaction with the hedgehog
ligand, as suggested by recent structural and biochemical studies.Several recent reports described the interaction of ShhNwith human
PTCH1 in detail. Gong et al. (20) obtained a high-resolution cryogenic
electron microscopy (cryo-EM) structure of PTCH1 bound to a bacte-
rially expressed ShhN fragment, including residues 39 to 190 of human
ShhN. The structure featured the ligand bound to the two ectodomains,
with extreme N- and C-terminal portions of ShhN unresolved. Sep-
arately, Qi et al. (21) solved a cryo-EM structure of PTCH1 bound to
a native ShhN fragment that includes the palmitoylated N terminus,
including residues 24 to 188. Contrary to the structure reported by
Gong et al. (20), this reconstruction showed that the N terminus of
the ShhN ligand is buried deep within the receptor, with palmitoyl
moiety wedged within the “neck” region between the ectodomain
and the membrane-embedded part of the receptor. The density of
the hedgehog ligand in this reconstruction was inconsistent with that
reported by Gong et al. (20). This inconsistency was settled by the
same authors who followed their study with a structure of a native
ShhN-bound PTCH1 captured in a state, where two PTCH1molecules
A and Bwere bound to ShhN via a ShhN-core interface (PTCH1B) and
via the palmitoylated N terminus of ShhN (PTCH1A) (22). This re-
markable structure explained the seemingly contradictory results ob-
tained previously with the monomeric PTCH1 molecules trapping
the bound ligand in opposite orientations. The structure also
provided structural evidence supporting the previously reported
ability of an acylated 22-residue N-terminal peptide of ShhN to ac-
tivate the hedgehog pathway by direct interaction with PTCH1 (23).
All three of the published structures of PTCH1 featured two extra den-
sities corresponding to sterols bound at the lipid-protein interface of
PTCH1 (20–22). Recently, a ligand-free PTCH1 structure was reported,
featuring a dimeric arrangement of the mouse PTCH1 homolog. The
ligand-free mouse PTCH1 displayed several lipid-like density elements
along a duct connecting the outer leaflet SSD region and the lipid site in
the extracellular domain (ECD). Supported by biochemical evidence,
the structure suggested a possible role of PTCH1 in cholesterol transport
as a mechanism of SMO regulation (24).
Previous studies identified several ShhN variants that can be used for
hedgehog pathway activation, with differing efficacies (25). The dually
lipid-modified ShhN showed the highest potency of activation, whereas
the unmodified ShhN fragment was the least effective in vitro. Substi-
tution of the C24 residue of the nonlipidated ShhNwith two Ile residues
(C24II-ShhN, here referred to as ShhNC24II) resulted in a substantial
increase in the activity of the ShhN fragment. Since the discovery of this
effect of the C24II substitution on ShhN, the ShhNC24II has become an1 of 9
SC I ENCE ADVANCES | R E S EARCH ART I C L Eindispensable tool in a wide range of studies of the hedgehog pathway.
On the basis of the close to native activity of the ShhNC24II ligand, struc-
tural characterization of the PTCH1-ShhNC24II complex should accu-
rately describe the recognition of the native hedgehog ligand by its
receptor, PTCH1.RESULTS AND DISCUSSION
To gain insights into the recognition of the modified ShhNC24II
hedgehog ligand by PTCH1, we solved the cryo-EM structure of the
human PTCH1 in a complex with ShhNC24II. The protein construct
PTCH1D combining the C-terminal truncation (residues 1 to 1188)
and the Y645Amutation, devoid of the two PPXYmotifs recognizedQi et al., Sci. Adv. 2019;5 : eaaw6490 18 September 2019by the HECT E3 ligases (26, 27), had excellent biochemical properties
and was used for structure determination (Fig. 1A and fig. S1, C to E).
The ligand, ShhNC24II, was generated by the expression in Escherichia
coli as an N-terminally SUMO (small ubiquitin-like modifier)–tagged
fusion (fig. S1, A andB). The purified ShhNC24II proteinwas biologically
active, with an apparentmedian effective concentration (EC50) an order
of magnitude lower than that of the recombinant human ShhN (Fig.
1B). The protein was mixed with the purified PTCH1D at a 2:1 molar
ratio and subjected to cryo-EM analysis (figs. S2 and S3). The cryo-
EM map obtained by image processing of the PTCH1D-ShhNC24II
dataset was refined to 3.4-Å resolution and was used for building a
complete model of the complex (Fig. 1, C and D, and fig. S3). The
atomic model of PTCH1D-ShhNC24II covers the sequence of PTCH1 o
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Fig. 1. Structure of the PTCH1D-ShhNC24II complex. (A) A schematic representation of the constructs used in this study. For comparison, the wild-type full-length
proteins (PTCH1 and ShhN) are shown. (B) The hedgehog pathway activation assay confirms the functionality of the ShhNC24II preparation. NIH 3T3 cells were treated
with the indicated concentrations of the ligands, and hedgehog pathway activity was evaluated analyzing Gli1 mRNA levels by qPCR; error bars indicate SD (n = 3).
(C) Density map of the reconstituted PTCH1D-ShhNC24II complex. (D) The views of the modeled complex corresponding to the views shown in (C). The key compo-
nents of the complex are labeled, including the TM1–6 (“M1”), TM7–12 (“M2”), and the extracellular domains (ECD1–2). (E and F) Comparison of the structure to the
previously solved PTCH1-ShhN (E) and PTCH1:rhShhN 2:1 complex (F). The bound ShhNC24II perfectly aligns to the previously observed complexes mediated by the
metal-binding site interface of the ligand.2 of 9
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residues F614-T728. The model features six well-resolved glyco-
sylation sites, the extended N terminus of the protein, and a part
of the intracellular loop 3 (IL3), which were missing in the pre-
vious reconstructions of PTCH1 (Figs. 2 and 3, A and B, and fig. S4).
Comparisons of PTCH1D-ShhNC24II and the two previously pub-
lished reconstructions revealed that the unmodified ShhN binds in a
near-identical manner (Fig. 1, E and F). The N terminus of ShhNC24II,
similar to that of ShhN, projects outside of the PTCH1 tunnel (Fig. 1E);
the divalent metal-binding site of the hedgehog ligand is close to the
PTCH1 binding interface. Comparison to the rhShhN (recombinant
human ShhN)–bound PTCH1 structure shows that PTCH1D bound
to the ShhNC24II matches the B chain of the dimer (Fig. 1F).
Similar to the previously published reconstructions, our cryo-EM
map contains four strong density elements likely corresponding to
the bound sterol molecules (Fig. 2), here denoted as site 1 (at the outer
leaflet portion of the SSD; Figs. 2 and 4, A and B), site 2 (at the binding
site formed by TM9, TM11, and TM12; Figs. 2 and 4, A and B), site 3
(buried within the ECD region; Fig. 2, A and C), and site 4 (at the inner
leaflet of the SSD; Fig. 2, B toD). The neck region of the protein features
a partial density element (site 0; Fig. 1A, inset), indicative of partial oc-
cupancy by an added sterol or a copurified lipid-like molecule.Qi et al., Sci. Adv. 2019;5 : eaaw6490 18 September 2019The structure of PTCH1D-ShhNC24II revealed a previously un-
identified feature: the presence of eight prominent density elements
at the protein-lipid interface, additionally to sites 1, 2, and 4 (Figs. 2,
A to E, and 4, A and B). These novel positions of the bound sterols
became apparent with the improvement of the density map
corresponding to PTCH1D. The focused refinement of the TM domain
of PTCH1D led to a density map at 3.3-Å resolution, allowing us to
describe the membrane-embedded portion of the protein with an un-
precedented level of detail (Fig. 3B, fig. S3, andmovie S1). The positions of
the membrane-embedded sterols surround the PTCH1D at sites within
SSD (TM2–6), at the SSD-like region of the protein corresponding to
TM8–12 (here referred to as “SSDL”), and at several sites not in direct
contact with either SSD or SSDL (Fig. 2, C to E).
Sites 1, 6, and 7 occupy the outer leaflet “pocket” of the SSD
(Fig. 2, B to D). Site 5 is located at the inner leaflet portion of the
SSD adjacent to the pocket (Figs. 2, C and D, and 3). Site 4 sterol at
the SSD is sterically separated from site 5 by the TM1 (Figs. 2, C and
D, and 4, A and B). The outer leaflet SSDL region is decorated with
sterols at sites 2 and 10. Sites 8 and 9 are adjacent to the TM7. The site
11 sterol is located apart from other sterol molecules, bound to the
N-terminal a helix that precedes TM1 and lies parallel to the lipid bi-
layer plane (Fig. 2, C and E). o
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Fig. 2. Bound sterol molecules revealed by the PTCH1D-ShhNC24II structure. (A) The 3D reconstruction features several well-resolved density elements in the ECD
region and surrounding the TM domains of PTCH1D (isolated density are colored yellow). The SSD (TM2–6) and the SSDL (TM8–12) are colored orange and blue. Inset:
Previously observed sterol sites are indicated as sites 1, 2, and 3; additional partial density is present in the neck region of PTCH1D (site 0, pink), suggesting partial
occupancy of the site. (B) Focused density map of the TM region (TM map) indicates the well-resolved sites 1, 2, and 4, as well as a number of novel sites, indicated with
a mesh; the pocket region within the SSD and the corresponding SSDL is indicated by a rounded rectangle. (C) The CHS molecules were modeled into the well-defined
density map regions (B) using 10s cutoff of the unsharpened refined density map. The closed circles correspond to the novel sterol sites revealed by the PTCH1D-
ShhNC24II reconstruction. (D and E) Views of the sterols surrounding the SSD and SSDL domains. The protein model is shown as a surface, colored according to atom
type; carbon atoms in the SSD and SSDL are colored orange and blue, respectively.3 of 9
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 The presence of the well-resolved density of the sterol site 5 explains
a previous observation of functional coupling between residues in this
region and the activity of the SSD domain–containing proteins. It has
been shown previously that D443N mutation in the SSD of SCAP
(sterol regulatory element-binding protein cleavage-activating protein),
an endoplasmic reticulum (ER)–resident SSD-containing protein, dis-
rupts the cholesterol sensitivity of the protein (28). A substitution of the
equivalent residue D584 to an asparagine in Drosophila melanogaster
Patched affected the ability of the protein to repress smoothened (29).
It is noteworthy that a similar mutation, D585N, in a mouse PTCH1
homolog appeared to have little or no effect on the function of the pro-Qi et al., Sci. Adv. 2019;5 : eaaw6490 18 September 2019tein under cell culture conditions, indicating that the effect of this SSD
mutation may be species or cellular context specific (30). Our recon-
struction shows that the sterol bound at site 5 is in immediate proximity
to D599 (Figs. 2 and 3A), corresponding to D443 of the yeast SCAP or
D584 of the Drosophila Patched. Comparison of PTCH1D to the x-ray
structure of NPC1, a cholesterol transporter homologous to PTCH1,
showed that a very similar structural motif is present in both proteins,
likely forming a structurally conserved sterol binding site (Fig. 3B).
Sequence alignment of PTCH1 and SSD domain–containing proteins
further confirmed the conservation of the residues in the region proximal
to the site 5 sterol in PTCH1 andNPC1, twoRNDproteins presumed to
be involved in cholesterol transport (Fig. 3C).
Structural alignment of the two pseudosymmetric intramembrane
halves of PTCH1D, using the SSD and SSDL regions for alignment,
showed that most of the bound sterol molecules appear to be unique
to the observed binding sites (Fig. 4, A and B). However, there is a clear
overlap between the pocket sterols: sites 1, 6, and 7 in the SSD and site
10 in the SSDL. This points to a possibility of a conserved role of both
domains of the protein in the interaction with the sterols, in line with
the previously proposedmodel where cholesterolmay access the inner
tunnel at the neck region within PTCH1 from both sides (22). This
would also be consistentwith the presence of disease-linkedmutations
on both sides of PTCH1 (fig. S5A). The mutations at the SSD side,
more densely populated with bound sterol molecules, coincide with
the residues directly involved in sterol binding (fig. S5B). Themutations
linked to holoprosencephaly 7, disrupting hedgehog signaling (3, 31),
and the mutations linked to the basal cell nevus syndrome, inducing
aberrant hedgehog signaling (32), have been mapped to the SSD and
the SSDL regions of PTCH1 (fig. S5, B and C), suggesting a likely func-
tional conservation of the two domains.
The PTCH1D-ShhNC24II structure provides the missing clues for
linking the putative sterol translocation pathway from the inner to
the outer leaflet of the SSD (Fig. 4, A toC). The existence of this pathway
was proposed by the recent reports (24), and our structure suggests the
plausible routes for the sterolmovement along the SSD surface from the
inner to the outer leaflet of the lipid bilayer (Fig. 4C). The SSD domain
of PTCH1 is capable of accumulating multiple sterol molecules in the
pocket as well as at the inner leaflet of the lipid bilayer. It is possible that
the presence of ShhNC24II, a ligand that blocks the activity of PTCH1,
establishes the conformation of the PTCH1 conducive to the accumu-
lation of the sterols at the sites along the translocation pathway. The
observed sterol sites are likely functionally coupled, as a number of
mutations in this region abolish the activity of the protein, as described
above. Furthermore, the presence of sterols at equivalent positions in
the pocket region of the SSDL region of PTCH1 indicates that this
domain may play a similar role as that of the SSD. Although the SSD
regions have been defined on the basis of sequence similarity to the
SSD regions in 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase and SCAP (33), it has been noted previously that the distinc-
tion between the SSD and the regions corresponding to the SSDL
domain in the RND family proteins may be somewhat arbitrary (18).
The structural comparison of SSD and SSDL in PTCH1D confirms this
suggestion and points at the functional similarity of these domains in
sterol recognition (Fig. 4, A and B).
To test whether disruption of sterol sites in PTCH1 SSD and SSDL
may have a direct effect on the hedgehog signaling, we designed several
mutations in the corresponding TM regions of PTCH1 (fig. S6). Muta-
tions to a bulky residue (Trp) were chosen to disrupt the sterol sites 1
and 6 (L116W; fig. S6A), site 5 (M598W; fig. S6B) in the SSD, and5
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Fig. 3. The inner leaflet SSD sterol site points at a functional role in PTCH1.
(A) The site 5 sterol (as defined in Fig. 2B; colored yellow) is within contact of the
residue D599, previously shown to be functionally critical in the SSDs of SCAP and
Drosophila Patched. (B) A similar site, unoccupied by a sterol molecule, has been
previously observed in the structure of the cholesterol transporter NPC1, homol-
ogous to PTCH1. The PTCH1D-ShhNC24II structure was aligned to the NPC1 X-ray
structure (cyan). Inset: Alignment of the two structures using the residues of
TM6 shows a great degree of similarity in the region surrounding the site 5 sterol.
(C) Sequence alignment of key SSD-containing proteins, PTCH1, DISP1, NPC1, HMG-
CoA reductase, and SCAP, shows the similarity between the elements involved in
inner leaflet sterol binding site. The pink arrow indicates the residue D599 [shown
in (A)]. The cyan bar corresponds to residues shown with side chains in (B). TM6 and
IL3 of PTCH1 are indicated below the sequence alignment.4 of 9
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 site 10 (T768W; fig. S6C) in the SSDL. The rationale for the Trp muta-
tions was to sterically hinder potential movement of the substrates at
these sites. The plasmids encoding the wild-type and the mutated
PTCH1 and PTCH1D were transfected into the PTCH1−/− cells together
with a luciferase hedgehog signaling reporter, and the pathway activation
was assessed (fig. S6D). The mock-transfected cells showed constitutive
pathway activation, as expected for the PTCH1−/−mouse embryo fibro-
blasts (MEFs). In contrast, all of the constructs, including the wild-type
PTCH1 and PTCH1D controls and the mutants, were capable of in-
hibiting the pathway activation (fig. S6D). The same was true for theQi et al., Sci. Adv. 2019;5 : eaaw6490 18 September 2019double mutants featuring simultaneously mutated SSD and SSDL outer
leaflet sites. This experiment does not rule out the involvement of the
observed sterol sites in substrate transport by PTCH1. However, it is
clear that mutating the sterol sites in PTCH1 may not suffice to shut
down the downstream pathway activation. It is possible that the muta-
tions do not fully obstruct the sterol sites to prevent sterol translocation
by PTCH1. It is also possible that the mutations have a direct effect on
sterol transport by PTCH1, but the residual activity of the protein is
sufficient to block the downstream pathway activation (i.e., the assay
is likely not sensitive to different levels of PTCH1 activity). A reductionA
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Fig. 4. Sterol binding site overlap observed at the SSD and SSDL domains of PTCH1. (A and B) The M1 and M2 regions of PTCH1D were aligned using the SSD
(orange) and SSDL domains (blue). The SSD and SSDL regions are represented as cartoons; the TM helices TM1 and TM7 are shown as ribbons. Sterols bound at the SSD
(yellow) and SSDL regions (light blue) are labeled using corresponding colored circles. The outer leaflet sites 1, 6, and 7 at the SSD and site 10 at the SSDL overlap. The
dotted lines in (A) and (B) indicate access of sterols via the inner leaflet to site 5 (SSD) and via the outer leaflet to pocket sites 1, 6, and 7 (SSD) and site 10 (SSDL). (C) Putative
model of sterol translocation via PTCH1. Left: In the absence of hedgehog ligand (red), the protein (illustrated using PDB ID: 6D4H) moves the inner leaflet sterols along the
path formed by the SSD. Right: Binding of the ligand negatively regulates this activity; the sterols accumulate at the SSD pocket region, evidenced by our 3D reconstruction.
Presence of sterols at the SSDL, along with its similarity with SSD, may suggest a similar functional role (marked by the dashed lines).5 of 9
SC I ENCE ADVANCES | R E S EARCH ART I C L E
http://advances.sciencem
a
D
ow
nloaded from
 of cholesterol transport activity of any PTCH1 mutant could be com-
pensated by the superphysiological expression of the constructs. The
development of molecular tools to directly track cholesterol move-
ment facilitated by PTCH1 will be necessary to address this point
experimentally.
Several well-resolved sterol densities are present in our three-
dimensional (3D) reconstruction at sites distinct from the SSD and
SSDL (sites 8, 9, and 11). The sterols bound at these sites may play
an important structural role, stabilizing themembrane-embedded parts
of the protein. These sitesmay also have a functional role, either directly
participating in the substrate flux mediated by PTCH1 or by modulat-
ing its activity in various lipidic environments within or outside of the
cilia membrane. The role of each lipid interaction will require careful
investigation, and our structure provides the framework for the future
in-depth analysis of the protein-lipid interactions in PTCH1 and other
SSD domain–containing membrane proteins.
Although our reconstruction features a monomeric state of the pro-
tein, the previously published biochemical evidence suggested that the
hedgehog pathway RND proteinsD. melanogaster Ptch (34) and Disp1
(35) may exist as trimers, similarly to bacterial RND transporters. Re-
cent structural studies showed that Shh-mediated dimerization (22) and
tetramerization of PTCH1 may also be possible (36). One or more of
these oligomeric states, or combinations thereof, may be required for
PTCH1 to act as a sterol transporter. In this case, the sterol translocation
pathway may be formed at the interface between the adjacent PTCH1
molecules. It is likely that PTCH1-mediated sterol transport may in-
volve several distinct stages, including interactions in the plane of the
membrane followed by movement of the sterol to the extracellular
space. Future investigations will address how the interplay of the sterol
sites, the ion transport, and the oligomerization of PTCH1 contribute to
its role as a sterol transporter and a master regulator of the hedgehog
signaling pathway. o
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PTCH1 expression and purification
The syntheticDNA fragment (Genewiz) encoding the humanwild-type
full-length PTCH1 protein (UniProt ID: Q13635) was cloned into
pcDNA3.1 vector modified to contain a C-terminal green fluorescent
protein (GFP)–10xHis tag fusion protein. PTCH1 was previously
shown to be recognized by the HECT E3 ubiquitin ligases, via two
PPXY motifs in the C terminus (residues 1313 to 1316) and in the cy-
tosolic loop (residues 642 to 645) (26, 27). Disruption of these motifs
was shown to reduce PTCH1 degradation (27). Thus, we designed
the PTCH1 expression construct to maximize the protein yield by re-
moving the two PPXYmotifs; the C-terminally truncated version of the
protein, PTCH1-C (residues 1 to 1188), and the construct PTCH1D
(comprising the residues 1 to 1188, with amutationY645A) were gen-
erated by polymerase chain reaction (PCR). The latter was subcloned
into a modified pACMV plasmid (37), resulting in an expression
cassette containing the PTCH1 construct fused to the C-terminal
3C-YFP-twinStrep tag. This was used to generate a stable tetracycline-
inducible human embryonic kidney (HEK) 293-GnTi− cell line expressing
PTCH1D.
Small-scale expression tests were performed using HEK293F cells.
Expression plasmids encoding GFP-tagged wild-type full-length
PTCH1 and derivative constructs were transfected into the HEK293F
cells grown in six-well plates using a polyethylenimine (PEI)–based
method in six wells. Cells were harvested 48 hours later by centrifu-Qi et al., Sci. Adv. 2019;5 : eaaw6490 18 September 2019gation, resuspended in buffer A [50 mM tris-HCl (pH 8.0), 200 mM
NaCl, 10% glycerol], and sonicated and solubilized using 1% dodecyl
maltoside (DDM). The lysates were centrifuged for 30min at 25,000g
(Eppendorf), and supernatants were analyzed by SDS–polyacrylamide
gel electrophoresis and in-gel fluorescence using Amersham Imager
600 (GE: 29083461).
For large-scale expression, the PTCH1D cell line cultures were
expanded to 5 liters in 2-liter Erlenmeyer flasks at 37°C in protein
expression medium (PEM) supplemented with 5% fetal calf serum
(FCS), penicillin/streptomycin, GlutaMAX, and nonessential amino
acids until cell density of 2 × 106 cells/ml was reached, and the expres-
sion of the protein was induced by adding 2 mg/ml tetracycline and
5mM sodium butyrate. Cells were grown for an additional 48 hours
at 37°C and were subsequently collected by centrifugation at 500g,
frozen, and stored at −80°C until the day of the experiment.
For protein purification, the frozen pellets of 5 liters of HEK293-
GnTi− cells expressing PTCH1 were resuspended in 150 ml of buffer A
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and
one tablet per 50 ml of Roche complete protease inhibitor cocktail
(EDTA free). Cells were homogenized using a Dounce homogenizer
andwere solubilized directly by the addition of 1%DDMand 0.2% cho-
lesteryl semisuccinate (CHS) at 4°C for 1 hour. The lysateswere clarified
by centrifugation (Ti45 rotor, 35,000 revolutions per minute, 30 min).
The supernatants were added to 3 ml of cyanogen bromide (CNBr)–
sepharose resin coupled with a purified anti-GFP nanobody (38).
Following 1 hour of incubation with slow rotation at 4°C, the resin
was collected in a gravity column (Bio-Rad), washed with 30 column
volumes of buffer A containing DDM/CHS mixture (0.025% DDM/
0.005% CHS) and with 10 column volumes of buffer A containing
0.1% digitonin. The protein was eluted from the resin by cleavage with
3C protease overnight at 4°C. The eluted fractions were passed through
1ml ofNiNTA resin to remove the 3Cprotease. The proteinwas further
purified using size exclusion chromatography using Superose 6 Increase
10/300 GL column equilibrated in buffer B [50 mM tris-HCl (pH 8.0),
100 mM NaCl, 0.1% digitonin]. The eluted fractions corresponding to
PTCH1 were concentrated to 5 mg/ml (~38 mM) using an Amicon
Ultra-4 concentrator (100 kDa cutoff, Millipore) and used for cryo-EM
grid freezing immediately.
ShhNC24II expression and purification
The synthetic DNA fragment (Genewiz) encoding the human
ShhNC24II protein (residues 25 to 197, modified at the N terminus
with a Cys24-Ile-Ile substitution; UniProt ID: Q15465), fused with the
N-terminal 6xHis-SUMOtag,was cloned intopET28aplasmid.The plas-
mid was transformed into BL21(DE3) RIPL E. coli cells. The transformed
cultureswere grown in a shaking incubator at 37°CuntilOD600 of 0.8, at
which point the temperature was switched to 30°C and the expression
was induced with 1 mM isopropyl-b-D-1-thiogalactopyranoside (IPTG).
After 3 hours, cells were collected by centrifugation, frozen, and stored at
−80°C until the day of the experiment.
ShhNC24II-expressing E. coli pellets (0.5-liter culture) were thawed,
resuspended in 10 ml of buffer C [50 mM tris-HCl (pH 7.5), 200 mM
NaCl] containing 25 mM imidazole, disrupted by sonication, and
cleared using centrifugation with a benchtop Eppendorf centrifuge
for 30 min at 25,000g. The supernatant was added to 0.5 ml of NiNTA
resin, incubated with rotation for 1 hour. The resin was collected on a
gravity column (Bio-Rad), washed with 30 column volumes of buffer C
containing 25 mM imidazole, followed by 10 column volumes of
buffer C containing 50 mM imidazole. The protein was eluted with6 of 9
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 buffer C containing 250mM imidazole. The eluted fractionswere pooled,
diluted eightfold to reduce the concentration of imidazole, and incubated
with 250 mg of purified SUMO protease Ulp1 overnight at 4°C. The
mixture was passed through 1 ml of immobilized NiNTA resin to re-
move uncleaved protein, excess cleaved SUMO tag, and Ulp1, and the
flow-through was concentrated to 1 ml and applied to a Superdex 200
Increase 10/300 GL column. The fractions corresponding to ShhNC24II
were pooled, supplemented with 10% glycerol, aliquoted into 100-ml
batches, flash frozen in liquid nitrogen, and stored at −80°C. Prior to
cryo-EM grid freezing, the protein was thawed, desalted into buffer B,
and concentrated to a final concentration of ~76 mM using an Amicon
Ultra-4 concentrator (10-kDa cutoff, Millipore).
Hedgehog reporter assays
To evaluate hedgehog pathway activation inNIH 3T3 cells, quantitative
PCR (qPCR) assays were performed. Confluent cultures of NIH 3T3
cells were starved overnight in Dulbecco’s modified Eagle’s medium
(DMEM) and treated for 24 hours with different concentrations of ei-
ther rhShhN or ShhNC24II. Following incubation, RNA was extracted
using the RNeasy Mini Kit (Qiagen) and reverse transcribed using
the QuantiTect Reverse Transcription Kit (Qiagen). Transcription of
the mouse Gli1 gene was measured by qPCR using KAPA SYBR FAST
(Sigma) on the LightCycler 480 System (Roche). mRNA expression of the
SDHA gene was used for normalization. The data (as shown in Fig. 1B)
were presented as fold enrichment with respect to the untreated sample.
The sequences for the gene-specific primers were as follows: Gli1,
GAATTCGTGTGCCATTGGGG (forward) and GGACTTCCGA-
CAGCCTTCAA (reverse); SDHA, TTCCGTGTGGGGAGTG-
TATTGC (forward) and AGGTCTGTGTTCCAAACCATTCC
(reverse). All qPCR experiments were performed in triplicate starting
from independent cell cultures.
The luciferase assays were performed in PTCH1−/−MEFs (the cells
were provided byM. P. Scott, Stanford University School of Medicine).
In brief, PTCH1−/− MEFs were transfected using the TransIT-LT1
Transfection Reagent (catalog no. MIR2304). For transfection, cells
were plated with the transfection mixture in 96-well plates. A mixture
containing the plasmids encoding 8xGli-BS firefly luciferase (39) and
cytomegalovirus (CMV)–Renilla luciferase (Promega), the latter consti-
tuting 1 10= of 8xGli-BS firefly luciferase plasmid, was added to the plas-
mids encoding the GFP, PTCH1, and PTCH1D constructs (1:1 with the
luciferase plasmid mixture). At confluence, cells cultured in DMEM in
the presence of 10 to 15% FCS were shifted to DMEM with 0.5% FCS
and incubated for 48 hours. Cell lysates were prepared following the
Dual-Glo Luciferase Assay System (Promega) protocol, and luciferase
activity was measured using the GloMax Explorer Multimode Micro-
plate Reader. For each sample, firefly luciferase values were normalized
to the corresponding Renilla luciferase values to account for the differ-
ences in transfection efficiency between samples.
Electron microscopy data acquisition
Toprepare cryo-EMgrids containing the PTCH1D-ShhNC24II complex,
the purified components, PTCH1D and ShhNC24II, were mixed at a 1:2
molar ratio, with a final concentration of PTCH1 of 2.5mg/ml (20 mM).
The complex was incubated for 10 min at room temperature, followed
by 30 min of incubation on ice. Aliquots of the protein mixture (3.5 ml)
were applied to the glow-discharged UltrAuFoil 1.2/1.3 Au 300-mesh
grids. The grids were blotted for 3 s, plunge frozen in liquid ethane using
Vitrobot Mark IV (Thermo Fisher Scientific), and stored in liquid ni-
trogen until the day of high-resolution data collection.Qi et al., Sci. Adv. 2019;5 : eaaw6490 18 September 2019Cryo-EMdata collectionwas performed using aTitanKrios electron
microscope (Thermo Fisher Scientific) equipped with a K2 Summit di-
rect electron detector (Gatan) and a GIF Quantum energy filter (slit
width of 20 eV) at EMBL Heidelberg. The micrographs were recorded
in counting mode with pixel size of 0.814 Å per pixel using SerialEM.
The defocus range was set from −0.6 to −2.5 mm. Each micrograph was
dose fractionated to 40 frameswith a total exposure time of 8 s, resulting
in a total dose of ~44.7 e−/Å2.
The cryo-EM dataset for PTCH1D-apo (ligand free) was collected at
BioEM Lab, C-Cina (University of Basel), using a similar setup (Titan
Krios, K2 Camera, QuantumGIF) andmethodology. The pixel size was
0.831 Å per pixel, and the defocus range was −0.8 to −3 mm; each mi-
crograph was dose fractionated to 40 frames with a total exposure time
of 10 s, resulting in a total dose of 75 e−/Å2.
Cryo-EM image analysis
A total of 7628 cryo-EMmovies weremotion corrected usingMotionCor2
(40). Contrast transfer function (CTF) was estimated using Gctf on non–
dose-weighted aligned images (41); micrographs with estimated resolu-
tion exceeding 4 Å were discarded, leaving 3260 micrographs for
downstreamprocessing.ThePTCH1D-ShhNC24II particleswereautopicked
in relion-2.1.0 using templates generated by 2D classification of 1306
manually picked particles (42), resulting in a selection of 707,620 parti-
cles. After several rounds of 2D classification, 430,811 particles were
selected for 3D classification. The procedure for 3D classification with
four classes was performed in relion-2.1.0, using a 3D model of
PTCH1D-apo low pass filtered to 30 Å. The initial model was generated
de novo in cisTEM using a dataset composed of 165,533 PTCH1D-apo
particles selected after 2D classification in relion-2.0. The best 3D class
of the PTCH1D-ShhNC24II complex consisted of 200,679 particles,
showed clear secondary structure elements (a helices), and featured a
bound molecule of the hedgehog ligand. This class was selected for 3D
refinement. Refinement of this class gave a map with a resolution of
3.6 Å [based on Fourier shell correlation (FSC) at 0.143]. Reprocessing
of this class using relion-3.0, including motion correction, CTF refine-
ment, and Bayesian particle polishing (43), resulted in a new map
with a resolution of 3.5 Å (“F”). Further refinement was performed
using the mask that excluded the detergent micelle, continuing from
the last iteration. This resulted in a map at 3.4-Å resolution. The same
procedure was repeated substituting the mask with a detergent and
ectodomain-free mask, resulting in a 3.3-Å resolution map after post-
processing. Postprocessing was performed in relion-3.0 using a B factor
of −50 Å2. The processing steps and map improvements are illustrated
in figs. S2 and S3.
Model building
Model building was performed in COOT (44) using the previously
solved structures of PTCH1 [Protein Data Bank (PDB) ID: 6DMY]
and ShhN (PDB ID: 3N1R) for guidance. Bound sterol molecules were
modeled as CHS (PDB code: Y01). The manually built model was re-
fined using phenix.real_space_refine (45) implemented in PHENIX
(46). Formodel validation, the atompositions of the refinedmodel were
randomly displaced by a maximum of 0.5 Å using the PDB tools in
PHENIX. The derived perturbed model was subjected to real-space re-
finement against one of the refined half maps (half-map1). Map versus
model FSC comparison was made for the model against the
corresponding half-map1 used in the refinement job, and for the same
model versus the half-map2 that was not used during refinement (47).
The model geometry was validated using MolProbity (48). Figures7 of 9
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Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
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Fig. S1. Purification of the hedgehog ligand and PTCH1.
Fig. S2. Cryo-EM and single-particle analysis workflow.
Fig. S3. FSC plots and 3D reconstruction details.
Fig. S4. Features of the map and the atomic model of the protein.
Fig. S5. Disease-linked mutations in PTCH1 are present within the SSD and SSDL regions of the
protein.
Fig. S6. Mutations designed to disrupt sterol binding sites in PTCH1 fail to suppress hedgehog
pathway activation.
Movie S1. The density elements corresponding to bound sterols in the PTCH1
TM-focused map.
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